UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 68

Sortiert nach

S619 Immune-Based Personalized Elimination Diet for the Treatment of Irritable Bowel Syndrome: A Double-Blind Randomized Sham-Controlled Study

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S454-S455

2023

Volltextzugriff (PDF)

Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFα Antagonists

Frontiers in immunology, 2019-12, Vol.10, p.2921-2921

2019

Volltextzugriff (PDF)

Diet-omics in the Study of Urban and Rural Crohn disease Evolution (SOURCE) cohort

Nature communications, 2024-05, Vol.15 (1), p.3764-3764, Article 3764

2024

Volltextzugriff (PDF)

Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening

Therapeutic advances in gastroenterology, 2022-03, Vol.15, p.17562848221083395-17562848221083395

2022

Volltextzugriff (PDF)

Infliximab levels and antibodies in IBD-related peripheral arthralgia

International journal of colorectal disease, 2020-06, Vol.35 (6), p.1141-1148

2020

Volltextzugriff (PDF)

Acute Chest Pain as an Infusion Reaction to Vedolizumab

Case reports in gastroenterology, 2022-06, Vol.16 (2), p.430-434

2022

Volltextzugriff (PDF)

Characterization of blood-derived exosomal hTERT mRNA as a biomarker for colon cancer and Lynch syndrome

Frontiers in oncology, 2022-09, Vol.12, p.962473-962473

2022

Volltextzugriff (PDF)

Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?

Biomedicines, 2023-05, Vol.11 (6), p.1553

2023

Volltextzugriff (PDF)

Adalimumab Level in Breast Milk of a Nursing Mother

Clinical gastroenterology and hepatology, 2010-05, Vol.8 (5), p.475-476

2010

Volltextzugriff (PDF)

Serum Syndecan-1: A Novel Biomarker for Pancreatic Ductal Adenocarcinoma

Clinical and translational gastroenterology, 2022-05, Vol.13 (5), p.e00473-e00473

2022

Volltextzugriff (PDF)

Serum MMP-9: a novel biomarker for prediction of clinical relapse in patients with quiescent Crohn’s disease, a post hoc analysis

Therapeutic advances in gastroenterology, 2019, Vol.12, p.1756284819881590-1756284819881590

2019

Volltextzugriff (PDF)

Significance of low level infliximab in the absence of anti-infliximab antibodies

World journal of gastroenterology : WJG, 2015-02, Vol.21 (6), p.1907-1914

2015

Volltextzugriff (PDF)

Immune function in newborns with in-utero exposure to anti-TNFα therapy

Frontiers in pediatrics, 2022-08, Vol.10, p.935034-935034

2022

Volltextzugriff (PDF)

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab

Gut, 2014-08, Vol.63 (8), p.1258-1264

2014

Volltextzugriff (PDF)

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

Clinical gastroenterology and hepatology, 2016-04, Vol.14 (4), p.550-557.e2

2016

Volltextzugriff (PDF)

A Murine Model for the Study of Molecular Pathogenesis of Radiation Proctitis

International journal of radiation oncology, biology, physics, 2010-01, Vol.76 (1), p.242-250

2010

Volltextzugriff (PDF)

Community-Based Safety, Immunogenicity, and Transmissibility Study of the Shigella sonnei WRSS1 Vaccine in Israeli Volunteers

Infection and Immunity, 2005-12, Vol.73 (12), p.8027-8032

2005

Volltextzugriff (PDF)

Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease

Clinical gastroenterology and hepatology, 2013-04, Vol.11 (4), p.444-447

2013

Volltextzugriff (PDF)

Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima

Gut, 2016-07, Vol.65 (7), p.1132-1138

2016

Volltextzugriff (PDF)

Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease

Journal of Crohn's and colitis, 2017-05, Vol.11 (5), p.jjw182-555

2017

Volltextzugriff (PDF)

Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases

Clinical gastroenterology and hepatology, 2018-05, Vol.16 (5), p.697-705.e7

2018

Volltextzugriff (PDF)

Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease

Journal of Crohn's and colitis, 2017-05, Vol.11 (5), p.549

2017

Volltextzugriff (PDF)

The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful

Gut, 2011-01, Vol.60 (1), p.41-48

2011

Volltextzugriff (PDF)

Mo1704 USING DIET-OMICS IN CROHN DISEASE TO IDENTIFY BENEFICIAL FECAL METABOLITES AND DIETARY COMPOUNDS THAT PROMOTE HEALTHIER MICROBIOME AND MUCOSAL TRANSCRIPTOMICS SIGNALS

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-871-S-871

2023

Volltextzugriff (PDF)

Mo1896 - Elevated Clinical Inflammatory Markers and Cytokine Expression in Peri- Diverticular Colonic Tissue in Patients Post Complicated Versus Uncomplicated Acute Diverticulitis

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S813-S814

2017

Volltextzugriff (PDF)

1 – 25 von 68

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(65)

Publikationsform

Artikel
(66)
Berichte
(2)

Sprache

Englisch
(68)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(41)
Life Sciences & Biomedicine
(40)
Humans
(33)
Gastroenterology & Hepatology
(27)
Adult
(23)
Female
(23)
Male
(20)
Inflammatory Bowel Disease
(14)
Inflammatory Bowel Diseases - Drug Therapy
(12)
Young Adult
(12)
Crohn Disease - Drug Therapy
(11)
Infliximab
(11)
Israel
(9)
Middle Aged
(9)
Biological And Medical Sciences
(8)
Gastroenterology And Hepatology
(8)
Adolescent
(7)
Antibodies, Monoclonal - Immunology
(7)
Antibodies, Monoclonal - Therapeutic Use
(7)
Ibd
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

S619 Immune-Based Personalized Elimination Diet for the Treatment of Irritable Bowel Syndrome: A Double-Blind Randomized Sham-Controlled Study

Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFα Antagonists

Diet-omics in the Study of Urban and Rural Crohn disease Evolution (SOURCE) cohort

Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening

Infliximab levels and antibodies in IBD-related peripheral arthralgia

Acute Chest Pain as an Infusion Reaction to Vedolizumab

Characterization of blood-derived exosomal hTERT mRNA as a biomarker for colon cancer and Lynch syndrome

Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?

Adalimumab Level in Breast Milk of a Nursing Mother

Serum Syndecan-1: A Novel Biomarker for Pancreatic Ductal Adenocarcinoma

Serum MMP-9: a novel biomarker for prediction of clinical relapse in patients with quiescent Crohn’s disease, a post hoc analysis

Significance of low level infliximab in the absence of anti-infliximab antibodies

Immune function in newborns with in-utero exposure to anti-TNFα therapy

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

A Murine Model for the Study of Molecular Pathogenesis of Radiation Proctitis

Community-Based Safety, Immunogenicity, and Transmissibility Study of the Shigella sonnei WRSS1 Vaccine in Israeli Volunteers

Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease

Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima

Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease

Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases

Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease

The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful

Mo1704 USING DIET-OMICS IN CROHN DISEASE TO IDENTIFY BENEFICIAL FECAL METABOLITES AND DIETARY COMPOUNDS THAT PROMOTE HEALTHIER MICROBIOME AND MUCOSAL TRANSCRIPTOMICS SIGNALS

Mo1896 - Elevated Clinical Inflammatory Markers and Cytokine Expression in Peri- Diverticular Colonic Tissue in Patients Post Complicated Versus Uncomplicated Acute Diverticulitis

Suchergebnisse filtern